Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press16810.17650/1994-4098-2011-0-2-Letters from CISГИНЕКОЛОГИЯ. НАМ ПИШУТ ИЗ СНГHigh-dose rate brachytherapy in the treatment of cancer of the cervix uteriБрахитерапия с высокой мощностью дозы в лечении рака шейки маткиAliyevD. A.АлиевД. А.
Azerbaijan
IsayevI. G.ИсаевИ. Г.
Azerbaijan
AkperovK. S.АкперовК. С.
Azerbaijan
kamal.akbarov@nco.azGuliyevE. G.ГулиевЭ. Г.
Azerbaijan
National Oncology Center, BakuНациональный центр онкологии, Баку25052011213082014130820142011https://ojrs.abvpress.ru/ojrs/article/view/168

Analysis of the results of examining and treating 246 patients with Stages IIA-IIIB cancer of the cervix uteri (CCU), receiving specific chemoradiotherapy (CRT) at the Department of Radiotherapy, National Oncology Center (Baku), has ascertained that CRT using two high-dose (9 Gy) rate brachytherapy fractions and competitive cisplatin chemotherapy is an effective, reasonably safe, and economically sound treatment method for locally advanced CCU. The method shows acceptable toxicity and may be used in routine clinical practice.

При анализе результатов обследования и лечения 246 больных раком шейки матки (РШМ) IIA-IIIB стадий, получивших конкурентную химиолучевую терапию (ХЛТ) в отделении лучевой терапии Национального центра онкологии Республики Азербайджан (Баку), установлено, что ХЛТ с использованием 2 фракций брахитерапии с высокой мощностью дозы (по 9 Гр) и конкурентной химиотерапией цисплатином является эффективным, достаточно безопасным и экономически выгодным методом лечения местно-распространенного РШМ. Метод характеризуется приемлемой токсичностью и может применяться в рутинной клинической практике.

cancer of the cervix uteribrachytherapychemoradiotherapycisplatinрак шейки маткибрахитерапияхимиолучевая терапияцисплатин1. Viswanathan A.N., Racine M.L., Cormack R.A. et al. 3D image-guided gynecologic brachytherapy: Practice patterns in the United States. Brachytherapy 2008;7(2):148.Viswanathan A.N., Racine M.L., Cormack R.A. et al. 3D image-guided gynecologic brachytherapy: Practice patterns in the United States. Brachytherapy 2008;7(2):148.2. Chi A., Gao M., Sinacore J. et al. Single versus customized treatment planning for multifraction intracavitary HDR brachytherapy for cervical cancer: Do we need to take the extra step? Brachytherapy 2008;7(2).Chi A., Gao M., Sinacore J. et al. Single versus customized treatment planning for multifraction intracavitary HDR brachytherapy for cervical cancer: Do we need to take the extra step? Brachytherapy 2008;7(2).3. Wang C.-J., Huang E.-Y., Sun L.-M. et al. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2004;59(1):179–89.Wang C.-J., Huang E.-Y., Sun L.-M. et al. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2004;59(1):179–89.4. Sakurai H. High-dose-rate 3D imagebased brachytherapy for uterine cervical cancer — evaluation of Japanese cervical cancer protocol based on gynecologic GEC- ESTRO recommendations. Brachytherapy 2008;7(2):156–8.Sakurai H. High-dose-rate 3D imagebased brachytherapy for uterine cervical cancer — evaluation of Japanese cervical cancer protocol based on gynecologic GEC- ESTRO recommendations. Brachytherapy 2008;7(2):156–8.5. Nag S., Erickson B., Thomadsen B. et al. The American brachytherapy society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;48:201– 11.Nag S., Erickson B., Thomadsen B. et al. The American brachytherapy society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;48:201– 11.6. Patel F.D., Rai B., Mallick I. et al. High- dose rate brachytherapy in uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 2005;62(1):125–30.Patel F.D., Rai B., Mallick I. et al. High- dose rate brachytherapy in uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 2005;62(1):125–30.7. Sood B.M., Gorla G., Gupta S. et al. Two fractions of high-dose rate brachytherapy in the management of cervix cancer: Clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys 2002;35:702–6.Sood B.M., Gorla G., Gupta S. et al. Two fractions of high-dose rate brachytherapy in the management of cervix cancer: Clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys 2002;35:702–6.8. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16.Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16.9. Cancer therapy evaluation program. Common Terminology Criteria for Adverse Events v3.0-CTCAE V3.0, DCTD, NCI, NIH, DHHS, http://ctep.cancer.gov.Cancer therapy evaluation program. Common Terminology Criteria for Adverse Events v3.0-CTCAE V3.0, DCTD, NCI, NIH, DHHS, http://ctep.cancer.gov.10. Aaronson N., Ahmedzai S., Bergman B. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer lnst 1993;85:365–75.Aaronson N., Ahmedzai S., Bergman B. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer lnst 1993;85:365–75.